NCT03928847View on ClinicalTrials.gov

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Epigallocatechin-3-gallate (EGCG)

Epigallocatechin-3-gallate (EGCG) capsules

Trial Locations (1)

94143

UC San Francisco, San Francisco

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Hal Chapman

OTHER

NCT03928847 - Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Biotech Hunter | Biotech Hunter